Project Grant R44CA203608

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a bioengineered lymphatic regenerating platform for the treatment of breast cancer related lymphedema (BCRL). The $491,029 award to William Marsh Rice University, granted on June 20, 2025, will fund the creation of an alginate mechacrylate (ALMA) hydrogel platform coated with an anti-fibrotic small molecule and containing programmable cell...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund a 5-year, $706,669 multi-site, triple-blind, placebo-controlled, Phase II randomized clinical trial to investigate the effects of photobiomodulation therapy (PBMT) on chronic lymphedema in head and neck cancer survivors. The principal goal is to evaluate the efficacy of PBMT for reducing the severity of external and internal lymphedema, as well as its impact on symptom burden and...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $642,639 Project Grant under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) to The University of Texas Southwestern Medical Center (UT Southwestern) to develop advanced imaging and analysis tools for lymphoscintigraphy in the diagnosis and management of lymphedema. This 3-year project, starting on September 1, 2025, aims to enhance the...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $502,294 to Georgia Tech Research Corporation to develop engineered biomaterials and targeted drug delivery approaches to promote lymphatic regeneration for the treatment of lymphedema. The key goals are to integrate advanced biomaterials, including lymphangiogenic hydrogels and lipid nanoparticles delivering vascular endothelial growth factor-C (VEGF-C) mRNA,...

This $818,625 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) will support a randomized clinical trial to evaluate two cardioprotective strategies - dexrazoxane and liposomal doxorubicin - for preventing heart failure in patients with diffuse large B-cell lymphoma who are at risk due to prior anthracycline exposure or pre-existing cardiomyopathy. The 5-year study aims to determine which...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $414,996 to the Trustees of Indiana University in Indianapolis to support research on the mechanisms of junctional proteins involved in post-surgical lymphedema. The research aims to advance the scientific understanding of lymphedema, a chronic condition affecting millions of Americans that often develops following surgical treatment of solid tumors. The...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $813,000 to Safeguard Surgical, Inc. to develop and evaluate a biodegradable barrier device called LeakGuard that can prevent anastomotic leaks in patients undergoing esophagectomy surgery. The key objectives of this SBIR Phase I project are to: 1) assess the mechanical and degradation properties of LeakGuard under esophageal-like conditions, and 2) demonstrate LeakGuard's ability to...

This National Science Foundation (NSF) Engineering Program (CFDA 47.041) award of $470,955 to Cornell University aims to develop a microfluidic cell culture platform to study breast cancer-associated secondary lymphedema. The 5-year project seeks to comprehend the regulation of lymphatic structure and function in breast cancer, and discover new treatment approaches for the over 150 million lymphedema patients worldwide. The research involves creating engineered lymphatic vessel models to analyze...

This federal Project Grant award of $156,500, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a study titled "Nurses Surviving Breast Cancer: An Exploration of Breast Cancer Diagnosis, Reported Lymphedema Symptoms, and Lifestyle Status in the Nurses' Health Study Survey". The study aims to 1) explore patterns of incidence of self-reported breast cancer-related lymphedema (BCRL) symptoms, and 2) examine...

This $817,829 Project Grant was awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The General Hospital Corporation (Massachusetts General Hospital) on September 12, 2025. The grant aims to test the efficacy of a virtual, resilience-based group program (SMART3RP-Lymphoma) to improve long-term quality of life for lymphoma survivors in the early post-treatment period (0-2 years after active treatment). The study will conduct a randomized controlled trial with 254...